Changeflow GovPing Pharma & Drug Safety Salts and Solid Forms of Piperidine-2,6-Dione f...
Routine Rule Added Final

Salts and Solid Forms of Piperidine-2,6-Dione for Treating Disorders

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

USPTO published patent application US20260098035A1 on April 9, 2026, covering novel salts and solid forms of (S)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione. Inventors Lianfeng HUANG, Daozhong ZOU, and Tsz Chung LAI filed the application on September 19, 2023, claiming pharmaceutical compositions for treating, preventing, and managing various disorders.

What changed

USPTO published patent application US20260098035A1 covering novel salts and solid forms of a specific piperidine-2,6-dione compound (CPC: C07D 413/14), with claims to pharmaceutical compositions and methods of treating various disorders.

Implications: Pharmaceutical companies developing or commercializing piperidine-based therapeutics should conduct patent landscape analysis to assess freedom-to-operate risks. Competitors may need to design around this patent or seek licensing arrangements. The publication date of April 9, 2026 establishes prior art for subsequent applications in this chemical space.

What to do next

  1. Monitor patent prosecution status for US20260098035A1
  2. Assess freedom-to-operate implications for competing piperidine compound developers
  3. Evaluate potential licensing or patent clearance requirements

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

SALTS AND SOLID FORMS OF (S)- OR RACEMIC 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND METHODS OF USING THE SAME

Application US20260098035A1 Kind: A1 Apr 09, 2026

Inventors

Lianfeng HUANG, Daozhong ZOU, Tsz Chung LAI

Abstract

Provided herein are salts of and solid forms comprising free base or salts of (S)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione. Pharmaceutical compositions comprising such salts and solid forms and methods of use of such salts and solid forms for treating, preventing, and managing various disorders are also provided herein.

CPC Classifications

C07D 413/14 A61K 31/5377 A61K 31/573 C07C 55/10 C07C 59/06 C07C 59/08 C07C 59/265 C07C 59/50 C07K 16/2896 C07B 2200/13

Filing Date

2023-09-19

Application No.

19113397

View original document →

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260098035A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent filing Drug formulation Therapeutic development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.